Correction: TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT

Xinxing Li; Shifeng Teng; Yanyan Zhang; Weigang Zhang; Xianwen Zhang; Kai Xu; Houshan Yao; Jun Yao; Haolu Wang; Xiaowen Liang; Zhiqian Hu

doi:10.18632/oncotarget.27299

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT

PDF | How to cite

Oncotarget. 2019; 10:6540-6540. https://doi.org/10.18632/oncotarget.27299

Metrics: PDF 1474 views | ?

Xinxing Li^1,*, Shifeng Teng^1,*, Yanyan Zhang^1,*, Weigang Zhang¹, Xianwen Zhang¹, Kai Xu¹, Houshan Yao¹, Jun Yao¹, Haolu Wang², Xiaowen Liang² and Zhiqian Hu¹

¹ Department of General Surgery, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China
² Therapeutics Research Centre, School of Medicine, The University of Queensland, Princess Alexandra Hospital, Woolloongabba QLD 4102, Australia
^* These authors have contributed equally to this work

Published: November 05, 2019

This article has been corrected: Due to errors in image processing, Figure 2C contains an image from the wrong cell line (GBC-SD cells). The corrected Figure 2C is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:47052–47063. DOI: https://doi.org/10.18632/oncotarget.16789.

Figure 2: TROP2 expression in GBC cell lines. (A) The TROP2 protein expression of human GBC cell lines NOZ, GBC-SD, OCUG-1, SGC-996 and EH-GB-1B. (B) The TROP2 mRNA expression of human GBC cell lines NOZ, GBC-SD, OCUG-1, SGC-996 and EH-GB-1B. (C) TROP2 mRNA expressions of GBC-SD and SGC-996 cells after RNA interference and plasmid transfection. Cells were transfected with scramble sh-RNA and empty vector as negative controls. Each experiment was repeated three times.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27299

Publication Alerts

Post-Publication Promotion

Corrections:

Correction: TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT